Anti-obesity drugs, a scientific breakthrough?

Anti-obesity drugsWith the prevailing lifestyle trends and work culture, most people are prone to being overweight or obese. The demographic of people diagnosed with obesity is constantly weighing down the healthy population. This area has thus provides extensive research opportunities to the pharmaceuticals and healthcare fields. The raised concern can also be attributed to the fact that obesity doesn’t continue as a sole health problem. It progresses to lead to varied chronic ailments thus reducing the life expectancy of a person.

Obesity has been identified to have genetic pre-disposition factors along with being caused by excessive food intake and lack of regular physical activity. But can any of these be resolved with medication?

Drug discovery and development

Developing a drug for obesity is difficult because mechanisms that regulate energy-balance in the body are in constant interaction with a number of physiological systems. The current understanding of human physiology suggests that the number of mechanisms for energy homeostasis and appetite regulation makes it difficult to engineer drugs for obesity. While targeting neurotransmission (for hunger and satiety) seems like the best alternative, it has a wide range of side effects.

Body-weight is also affected by psychological and social factors. So, it is a common belief that pharmacotherapy cannot solve the problem of obesity. Moreover, since weight gain results from lifestyle alterations, most people feel that behavioral changes alone can help weight management. But one needs to be informed that anti-obesity drugs exist and can help a person lose up to 5-15% of his body weight. This, however, lasts only till the treatment goes on. The maintenance of the weight loss differs in different subsets of individuals.

Is the shrink brought about without the suppression of diet?

The expansion of the Anti-Obesity Drugs Market stems from the FDA’s approval of five different kinds of drugs for weight management, each of which has a different mechanism of action.

  1. Phentermine/Topiramate ER

Phentermine works on the nervous system to suppress appetite. It is also known to increase metabolism.  The exact mode of action of the secondary compound, Topiramate, has not been elucidated. The two components are packed in a gelatin capsule, the former designed for immediate release and the latter in beads for extended release. The combination was shown to work with good efficiency in clinical trials.

  1. Orlistat

Orlistat falls in the lipase-inhibitor category of drugs. It works to prevent the absorption of fats by the intestines. The drug has to be supplemented with an everyday exercise routine for an efficient weight loss.

  1. Lorcaserin

Serotonin is a chemical substance in the body that signals satiety. Lorcaserin targets serotonin receptors in the hypothalamus region of the brain to inhibit appetite. Since it interferes with neurotransmission, its intake should be with great care.

  1. Naltrexone SR/Bupropion SR

This combination of drugs works on the hypothalamic melanocortin system and the mesolimbic reward system to reduce appetite. Although developed to help overcoming alcohol and opioid dependence, it is now also associated with weight reduction.

  1. Liraglutide 3.0 mg

Liraglutide can be used as an adjunct to a low-calorie diet for weight management. It delays gastric emptying and decreases hepatic glucose production to bring about a loss in weight.

The market size of these drugs:

Although there has been considerable research, the commercialization of the products has been less. Even the aforementioned drugs come with packaged warnings of a number of serious side effects. This indicates that no ideal anti-obesity drug has been established. The ideal one should cause minimal side-effects and the sustenance of weight loss should be prolonged. To attain a control over body-weight through drugs to the same extent as a surgery has not been possible so far. Global market research reports thus suggest many opportunities for entry into the field.

There must be a detailed behavioral analysis at various stages of drug development. This will help monitor the working of the drug at the molecular level. Only a recognized pattern of the physiological responses can aid the development of an ideal anti-obesity drug.

China: Planning to be the second largest pharmaceutical market

pharmaceutical-marketThe healthcare market of China has been rising at an exponential rate and is very soon poised to overtake Japan as the world’s second largest pharmaceutical market, after the U.S. The overall value of the Chinese pharmaceutical market is estimated to grow up to $ 315 million by 2020, a profuse 650% growth from $ 48 billion in 2013.

Several reformations have been decided by the country to include especially in the domestication of the rising cost health costs, in light of the recent ‘government initiated reforms’. The possible decrease in the prices of prescription medicines, owing to government intervention is likely to open up the yet unexploited and unserved share of the market of Chine, specifically in the interiors of China, where insurance is nearly absent and inexpensive for prescription drugs in the present market scenario is little. The rehabilitated medicine value intend to target the rural population of approximately 713 million people which encompasses around 55% of the country’s populace.

Predictions of Chinese Healthcare Market:

As the demand for healthcare rises, the government authorities are determined to shift focus from being merely an export-based financial system, to one that sells to the Chinese patrons. Various elements contribute towards this proposed growth, one such key factor is the growth of the new middle class. These groups of consumers can meet the expense of these western drugs, particularly the ones that are used to treat conditions such as respiratory illness and depression, which is formerly, would have gone typically untreated or undiagnosed.

This growth is estimated, despite of recent parade of probes in the medicine prices and fraudulent sales practices of major companies including Merck, Glaxo, Smith Kline, Abbot Laboratories  and Baxter International in China. According to a market research, even with this backdrop of prices issues and bribery, the Chinese pharmaceutical market is on the rim of substantial development.

Under the new projected healthcare program, China is offering enlarged insurance coverage to millions of new patients. Till 2020 overall expenditure on China’s healthcare market is predicted to rise to $1 trillion from $357 billion in 2011, beside a proposed investment of $160 billion in healthcare research and development.  Analysts expect that Chinese market is maturing; it means a regulated market, albeit a growing one.

Infectious diseases Diagnostics market to see growth in the next five years

Diagnosing infectious disease is a process when a healthcare professional identifies or distinguishes the cause of a contagious disease. This process is done by using different diagnostic tools that may be through laboratory tests, biopsies, and imaging scans.

The prevalence of the infectious disease is high in developing or underdeveloped places. This is majorly due to the lack of awareness about personal hygiene, healthcare, and methods of preventing diseases. Additionally, there is also the absence of skilled and trained healthcare professionals and pharmacies which lead to a high number of infectious diseases spread in those regions. Therefore such conditions have increased the international market for infectious diseases diagnostics market (IDD).

Companies identified this potential for growth and have started investing in this market. Moreover, they are now prioritizing on developing novel diagnostics which will be the main component in expanding and surging the growth of the market even further.

The global expansion of IDD international market

The global infectious disease diagnostics market is estimated to grow up to USD 18,156.2 million in value by 2019 from USD 12,422.8 million in 2014 as per a healthcare market report.  Moreover, the worldwide market is also predicted to grow swiftly at CAGR (Compound Annual Growth) of 7.9% in the predicted period of 2014 to 2019.

Product

Referring to the product, the consumables-category had the biggest share in the market in 2014. This segment is expected to keep leading in the forecast period, because of its adoption to the emerging contagious disease diagnostics worldwide.

Technology

On the basis of technology, INAAT (Isothermal Nucleic Acid Amplification Technology) and PCR (Polymerase Chain Reaction) are estimated to have the largest market share during the forecasted period. All the while, micro-rays, INNAT and NGS (Next Generation Sequencing) are predicted to witness the highest growth due to increasing demand for better specificity, connectivity and speedy turnaround time for diagnostics tests.

End User

On the basis of end users, the reference laboratories and hospital labs held the largest portion of the Infectious disease diagnostics market in 2014. It is also forecasted to keep dominating the market in the predicted time period as well.

Application

Among application basis, the human papillomavirus (HPV) and hospital-accessed MRSA infections (Methicillin-resistant Staphylococcus aureus) are estimated to exhibit the speediest growth in between the estimated period. This growth is cited for the rising emergence of contagious diseases over the last recent years.

Regionally

Geographically speaking, the market for transferable disease diagnosis is largely governed by North America and Europe. The market in Asia-Pacific (APAC) is forecasted to grow at the highest speed of 9.9% of CAGR during the estimated time. This is owing to the elevated number of transferable diseases in countries like India, China, Japan and Australia. Additionally, various awareness programs held in these regions are boosting the market. As the market is expected to get a huge boost in investment from respective governments the increase in healthcare expenditure is an advantage for contagious disease diagnostics industry. Countries like Australia, India, China and New Zealand are projected to be the key revenue makers for the market.

Elements that are influencing and restricting growth of the market

Two of the major factors that are influencing growth according to the Healthcare market research are –

Government investments

The governments all over the world have started increasing their funding towards identifying contagious diseases. Along with rising demand for speedy diagnostic techniques because of slow turnaround time in the current techniques, increasing prevalence of transferable diseases and government funding are some of the factors attributed to the growing market.

Advancement in Research and Development

There are huge growth opportunities in developing nations and advancement in R&D for bettering diagnostic technology and its popularity.

Some of the elements that are restricting its growth are –

Increasing healthcare costs, a complex regulatory framework that delays the approval of tests, lack of skilled professionals and problems regarding reimbursement situations are the challenges that are faced by the key players in the market.

Key players and the competitive strategies

Some of the key players in IDD market worldwide are Roche Diagnostics, BioMerieux, and Bio-Rad Laboratories, Thermo Fisher Scientific.inc, and Becton and Dickinson & Co. Their key strategies involve introducing new products, acquisitions, expansions and collaborations that strengthen their position in the industry.

The growth projected is definitely good, although, it’s a challenging market and hence it needs to keep fighting to uphold utility and market share. Some of the estimations are in bigger numbers which have been published but its research needs to offer a support for the better growth of the market.

The Growing Importance of Cord Blood and Stem Cell Storage

stem-cellCord blood and stem cell banking is one of the most important sector of healthcare today, especially when scientists are putting together skills to find answers to critical disease such as mental disorders, cancers, and more. The global stem cell market is hyping because of the cost effective means for treatment that has lesser side effects. From 2013 to 2020, the market may grow at CAGR 33% and account for $6.5 billion, as per the Stem Cell Market research report. Some of the segments in the industry are adult or embryonic stem cells.

There is huge help from government for supporting the clinical trials and research in cord blood stem cell and concurrent therapies.  Cord blood cells are simply the blood collected from the newborn’s umbilical cord while stem cells can be either from the baby or adult, such as ones taken from bone marrow. Both are essential and life saving, but the cord blood banking is increasing more as to the youthful and uncontaminated cells, which have higher efficacy and success rate.

Future Opportunities

As per a study, the global stem cell therapy market in forecast duration of 2015 to 2020 will growth at 39.5% CAGR to reach the worth of $330 million. Increasing public awareness is the main driver of the industry. There is an enhanced perception by people for cord blood cell and stem cell therapies. New clinical trial data is supporting applications for HSCs (hematopoietic stem cells) from mesenchymal stem cells and cord blood or tissue.

There has been rise in deal-making in the industry with acquisitions, funding, and mergers doing rounds. Cross-organizational collaboration is seen between U.S. and South America, with trend for diversification such as placental tissue, cord blood or tissue, amniotic fluid storage etc

Key Audiences and Regions

The major audiences for stem cell and cord blood cell storage are government and private research institutes, therapeutics service companies, academic institutes, private and public relevant banks, research based pharmaceutical companies, and more. The key regions leading in the industry are Europe, Asia-pacific, North America, and rest of the world. Huge potential is being seen in Asian region with developed countries like the U.S already keeping a steady score in the market.

Governing Bodies

The governing bodies for the global cord blood banking services are American Association of Tissue Banks (AATB), American Association of Blood Banks (AABB), Tissue Authority (HTA), Clinical Laboratory Improvement Amendments (CLIA), and others. Some of the challenges are shortage in storage of cord blood units and the expenses. Keeping up to hygiene and security protocols are some more points the industry has to focus on.

Segmentation by Technology

There has been a significant rise in cord blood and stem cell transplant that have enormous potential to heal deteriorating body organs and other parts. Brand awareness is one of the steps the key players are using to get people accustomed to their services. The global market by technology is divided into segments such as Stem Cell Transplant, Allogenic transplant, Cell Based Genetics, Autologous transplant, Regenerative Medicine, Blood Transfusion, Transplant Medicine, Cord Blood Banking, and others.

Treatment for Diseases

Some of the diseases that can get cured by cord blood cell or stem cells are Cancer/ Oncology diseases, Chronic Leukemia, Beta Thalassemia, Blood diseases, Leukocyte Adhesion Deficiency, Acute Leukemia, Sickle Cell disease, Hemophagoyticlymphohistiocytosis, High Risk Solid Tumors, Krabbe Disease, Osteopetrosis, Metabolic Disorders, Myelodysplastic Syndrome, Sanfilippo Syndrome, Wiskott-Aldrich, Hurler Syndrome, Immune Disorders, Hystiocytic Disorders, and Aplastic Anemia etc.

Medical Expertise

Dr. Sonali S. Shetye is one of the leading infertility specialists, and has a strong background in medical industry. Her expertise also lies in laparoscopy , Gynaecology and obstetrics. If you have any queries pertaining to specified fields, please feel free to contact us at contact@aarkstore.com for professional guidance.

MIT Chemists Introduce Effective Molecular Treatment for Deadly Cancers

Cancer_Cure

Every year, the world records 12 million cases of diagnosed cancer, and some its types can be treated with available treatments. But, there are some forms, which do not respond to present approaches. This is where drug delivery systems for cancer faces short-comes. Innovative and novel methods to treatments are being explored. These are based on micro-particle, which carry anti-cancer agents.

Such particles are injected in the affected person’s bloodstream, and directed to tumor through magnetic field of targeted drug reach. Professor Paula T. Hammond, the head of MIT’s Department of Chemical Engineering, opened up about the remedy in a conference. The team she leads us engineering a nano-particle that is one-hundredth measure of a human hair, and may be able to treat serious cancers that do not respond well to drugs.

However, the costs to trial of novel remedies today may seem a lot, In future it will yield good results. As per market research reports, clinical trials for global advanced drug delivery industry will stand at $227.3 billion by the year 2020. Here is how the super-powerful molecular treatment devised will fight deadly cancers.

New Molecular Treatment for Cancer

MIT chemists wish to create a cancer-restraining agent that will be introduced in patient’s bloodsteam, which goes to penetrate tumor tissues. The nano-particle will be small enough so as to get into the cancer cell. The nano-particle core is a tiny capsule which consists of chemotherapy drug. Thus poison will end life of tumor cells, and around the core, the experts will wrap thin nanometers of siRNA (small interfering RNA), a gene blocker.

The same is a strong negatively charged element that is covered by a protective later of polymer (positively charged). The oppositely charged molecules will stick together due to charge attraction that will give a protective later to prevent the siRNA deterioration in blood. The siRNA is a collection of molecules, which is utilized to stop a specific gene in a cell. The scientists are keen about the enormous clinical potention of such gene blockers for drug delivery and diagnostics.

A body has cells, which in bloodstream can attack anything that is foreign. The team and Hammond are devising a technique for deploying nano-particle without causing any problem to the patient. The way out was adding another negatively charged cover about the nano-particle that services the purpose of creating clod of water molecules for nano-particles for cloaking effect. It will also consist of molecules to bind at tumor cell. When in the cancer cell, it is easy to deploy the nano-particle.

Killing the Dangerous Tumor

When siRNA is employed, cancer cell is defenseless. A chemotherapy drug exudes from capsule to destroy tumor cells efficiently. On using sufficient measure of gene blockers, it is possible to answer many different types of mutations that will clear out other tumors without leaving remnants. The MIT researchers say that nano-particles were tested on animals with triple-negative breast cancer, and the therapy did reduce size of tumors, and some of the cancer cells were eliminated.

Hammond thinks her approach may be personalized. There are more treatments being tested and developed. According to the healthcare market research reports, the UT Southwestern Medical Center experts revealed findings of Stereotactic Body Radiation Therapy, which proved to be more effective than other traditional treatment, with cure rate of 98.6 percent.

As for siRNA therapy, it is backed by evidence that cardiovascular drug delivery is most innovative means in therapeutics underlying RNA interference. Rest is supposed to be seen how the treatment progressed. More clinical trials will be needed, until the drug delivery can be made available to health authority and organizations to give it a clean chit, and then present it to the market.

8 Must Know Health Care Prediction and Trends for 2016

 

With health data analytics and services moving to new avenues from 2015, the hope for medical industry looks positive in 2016. A number of activities in 2015 will influence patient engagement platform, pharmacies, and drug & device market in shaping strategies or policies. Here are the major 8 possible trends and predictions for healthcare 2016, which can pose the world to a better future.

1.     More of Wearables Health Devices

Medical wearables are gaining grounds as monitoring technologies, especially for diabetes and cardiovascular health. Some of the industry leaders are Proteus Digital Health, Vital Connect, and Neurometrix. As per healthcare market records, 29% of users depend on electronic personal records for health, 24% of customers use mobile applications to track wellness, while 16% utilize wearable sensors. But, very soon 47% of relevant consumers will use only wearables, whose market will hit $6 billion in few years.

2.     Economical and Speedy Point of Care Testing (POC)

New diagnostic care methods and models are spurting given faster and less expensive POC, as reported by leading market research firms. Some of the commercialized POC test platforms such as connectivity features, molecular POC, microfluidics, biosensors etc. will greatly enhance in turnaround times (about 5 to 15 minutes). This will allow testing services to become much more feasible.

3.     Free and Subsidized Preventive Care

Preventative services by government and private enterprises will overlook use of creative technology. Thus, care and cost burden on chronic diseases will reduce. Such cares will be accessible to everyone, engaging more consumers to meet their demands of optimum medical capacities. In pharmaceuticals and healthcare, the free preventive services for medical industry is industry is going to peak at 90%.

4.     Regenerative Medicine Market

Regenerative market in pharmacies is going to be the chief trend in 2016. As business is estimate to hike by 22.4%, investments in this niche is the ultimate goal. Favorable legislative policies are being formed in cell therapy market products as well. As per market research, the global regenerative medicine market in 2016 will reach $30 billion.

5.     Increase of Retail Primary Care

In 2015, a lot many investments were seen in medical footprint. New mergers, partnerships, and acquisitions were made to advance tools and health services. In 2016, these efforts will be continued with greater participation from retailers. They will plan to lead the primacy care facilities.

6.     New Development Bank (NDB) Expends on Pharma

NDB is worth $100 billion capital, an alternate to global banking zones dominated by European and American stakeholders. Previously it was Brazil, Russia, India, China, South Africa (BRICS) Bank. But, now NDB is focusing more on bettering lives of people from developing countries. It will invest in infrastructure for pharmaceuticals and healthcare, keeping in mind the undeserved populations.

7.     Population Health Tool

The growing need of population health tools is motivating companies to think differently. Organizations are becoming systematized and accountable, as the paradigm of compensation has taken place, cutting down issues of fallacies or corruptions. Even the health management of patients has improved.

8.     Retooling and Overhauling of Outdates Facilities

To avoid closure of clinics, the concerned organizations are doing everything from recourse utilization to reform hospital layout. In the healthcare market, we see such an overhauling initiative worth $1.3 billion by Dallas’s Parkland hospital. These institutions are seeking to adapt new care delivery systems to raise the patients’ satisfaction, than closing down their centers. 

Global Type 2 Diabetes Market to Seize the Mark of $39 Billion by 2021

The global market for the Type 2 diabetes is going to parade by 66% for the next seven years, as per research analysts. The target set is $39 billion by 2021. It will rise from the figures of $23.5 billion in 2015, given the drive of approved treatments. The conclusion is drawn on 3 classes of medicines. Glucagon-like peptide-1 (GLP-1) receptor agonists is the foremost, followed by sodium–glucose cotransporter 2 inhibitors and dipeptidyl peptidase-4 (DPP-4) inhibitors. These are advanced by Merck & Co’s Januvia, and a new entrant is Merck and Takeda.

Initiated by Janssen’s Invokana (canagliflozin), the sodium–glucose cotransporter 2 inhibitors have hit the market, while glucagon-like peptide-1 (GLP-1) receptor agonists’ newer version is begun from Novo Nordisk and Sanofi, as per the pharmaceuticals and healthcare market scan. The pipeline treatments are going to enhance in administration and dosing frequency methods. Some of these will help in lowering hypoglycemia, manage weight, and reduce side effects.

Advancements in Drugs and Treatments for Diabetes

The credible example are the two approved GLP-1 receptor agonists (once weekly), Trulicity and Tanzeum (oral drug), OG-217SC. This is the second phase of development. Similarly, ITCA 650, and osmotic pump given sub-dermally is in the third development phases, which needs once or twice dosing in a year, according to the market research report.

Few analysts say that the later stage pipeline treatment is seemingly more progressive. Already 16 products have made the pre-registration phase, while 33 products are in the third phase development. Significant growth in Type 2 diabetes market is expected from Spain, France, UK, Italy, and Germany. Other participants are Japan, US, and Canada along with the rest of the world